RecruitingNCT06607445

Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service.

Evaluation of the Implementation of the Pharmacogenetics and Personalized Medicine Program "MedeA" in the Extremadura Health Service. Population Cohort [MedeA21].


Sponsor

Complejo Hospitalario Universitario de Badajoz

Enrollment

6,445 participants

Start Date

May 26, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

An open longitudinal observational study, non-randomized, which will include the adult population, attended by the SES, in which preference will be given to those patients under treatment with drugs that can produce relevant adverse effects. It is a naturalistic study in which no pharmacological or other type of intervention will be carried out, only the information recommended in the drug data sheet (pharmacogenetic biomarkers, relevant interactions and clinical contraindications) will be provided.


Eligibility

Inclusion Criteria8

  • General criteria for all patients:
  • Age ≥ 18 years. In case of minors, they may be included, under the following assumptions:
  • If the minor is under 12 years of age, participation will require the consent and signature of the informed consent document by both parents (or their guardian).
  • If the minor is between 12 and 16 years of age, a proxy informed consent form will be provided and signed by both parents (if both parents are present at the time of the interview) or only one of them (in which case one of the following two conditions must be stated: that the other parent is not present at the time of the interview but does not object to the participation of the minor in the study or that the signatory is the sole legal guardian of the minor).
  • Be registered or potentially/have been attended in the Extremadura Health Service.
  • Not have language or communication barrier or present disability being totally dependent on another person.
  • Refusal by the patient to be part of the cohort initially, or to continue to be part of the cohort during follow-up.
  • Manifest difficulty for follow-up.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Complejo Hospitalario Universitario de Badajoz

Badajoz, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06607445


Related Trials